NIOX Group Plc Board recommends the payment of a final dividend of 1.25 pence per share
Financial highlights
Revenue growth of 14% to £41.8 million (2023: £36.8 million) and 16% on a constant currency basis.
Clinical revenue1 growth of 11% (14% on a constant currency basis) to £36.1 million (2023: £32.6 million).
Group adjusted EBITDA2 of £13.8 million, ahead of consensus estimates (2023: £11.4 million) and 21% growth on 2023.
A dividend of 1 pence per share (equating to a cash return of £4.2 million) was paid to shareholders in June 2024.
A tender offer was completed in October 2024, returning a further £21.0 million to shareholders.
Net cash of £10.9 million (31 December 2023: £19.9 million) after the above cash returns.
The Board recommends the payment of a final dividend of 1.25 pence per share in respect of the year ended 31 December 2024.
Revised capital allocation policy to increase cash returns to shareholders.
